Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Apellis Pharmaceuticals, Inc.

< Previous 1 2 3 4 Next >
Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Announces Craig Wheeler to Join the Board of Directors
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Announces Keli Walbert to Join the Board of Directors
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.